Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction modelFrancesco Vizzutti, Filippo Schepis, Roberto Miraglia et al.|Hepatology|2022Cited by 55
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Johann von Felden, Giuseppe Cabibbo et al.|Hepatology|2024Cited by 52
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future TrialsGiuseppe Cabibbo, Calogero Cammà, María Reig et al.|Liver Cancer|2021Cited by 50
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular CarcinomaGiuseppe Cabibbo, Calogero Cammà, Ciro Celsa et al.|Cancers|2020Cited by 34